KPV (10 mg Vial) Dosage Protocol
KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-MSH. It retains the anti-inflammatory and antimicrobial properties of α-MSH without the pigmentation effects.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 200 mcg | 6 units (0.06 mL) |
| Week 2 | 300 mcg | 9 units (0.09 mL) |
| Week 3 | 400 mcg | 12 units (0.12 mL) |
| Weeks 4–8 | 500 mcg | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to maintain manageable injection volumes. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability and more precise measurement.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (KPV, 10 mg each) | 8 weeks ≈ 3 vials 12 weeks ≈ 4 vials 16 weeks ≈ 6 vials |
| Insulin Syringes (U‑100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100‑count boxes 12 weeks: 168 swabs → recommend 2 × 100‑count boxes 16 weeks: 224 swabs → recommend 3 × 100‑count boxes |
Protocol Overview
KPV protocols vary significantly by indication — gut-focused (IBD, ulcerative colitis) protocols use higher doses with oral capsules added; systemic anti-inflammatory protocols use sub-Q daily; skin protocols often use topical alongside sub-Q.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
KPV is the active C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory activity of α-MSH but lacks the melanocortin pigmentation effects.
It downregulates NF-κB and pro-inflammatory cytokines (TNF-α, IL-6), modulates immune cell trafficking, and exhibits direct antimicrobial activity against bacteria, fungi, and yeasts. Studied in inflammatory bowel disease, atopic dermatitis, and acute inflammation.
Potential Benefits & Side Effects
Potential Benefits
- Anti-inflammatory effects across multiple tissue types.
- IBD model improvements via NF-κB downregulation.
- Antimicrobial activity (broad-spectrum).
- Skin condition improvements in atopic dermatitis models.
- Pairs well with BPC-157 for gut-mucosal protocols.
Side Effect Profile
- Generally well-tolerated.
- Mild injection-site reactions possible.
Lifestyle Factors
- Adequate hydration and electrolytes during gut-focused protocols.
- Anti-inflammatory diet (omega-3, low refined sugar) complements effects.
- Sleep adequacy supports immune regulation.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm. Rotate sites.
- Some IBD protocols use oral capsule formulations for direct gut exposure.